Avalo Therapeutics, Inc. · NASDAQ:AVTX

Sullivan Christopher Ryan sold 15,959 Avalo Therapeutics, Inc. shares (Form 4)

Traded Apr 1 to Apr 2, 2026 · Filed Apr 3, 2026

From Apr 1 to Apr 2, 2026, Sullivan Christopher Ryan (Chief Financial Officer) sold 15,959 Avalo Therapeutics, Inc. shares at an average US$16.96 for US$271K under a trading plan, leaving 17,338 shares. Filed Apr 3, 2026 (Form 4).

Sold
15,959 shares
Price
US$16.96 average (US$15.86 to US$17.57)
Value
US$271K
Holding after
17,338 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Apr 1, 2026Common StockSale500US$15.8632,797Direct
Apr 1, 2026Common StockSale7,479US$16.8325,318Direct
Apr 2, 2026Common StockSale6,200US$17.0219,118Direct
Apr 2, 2026Common StockSale1,780US$17.5717,338Direct

Source

View original at SEC

Related